Browse > Article

Method Development for the Profiling Analysis of Urine Globotriaosylceramide (Gb3) for the Screening of Fabry Disease by Tandem Mass Spectrometry  

Yoon, Hye-Ran (Dept. of Biomedical & Pharmaceutical Analysis, Duksung Women's University)
Cho, Kyung-Hee (Dept. of Analytical Research, BioCore Co., LTD)
Kang, Seung-Woo (Dept. of Analytical Research, BioCore Co., LTD)
Kwon, Young-Joo (Dept. of Internal Medicine, College of Medicine, Korea University)
Jeong, Choon-Sik (Dept. of Pabathophysiology & Pharmacology, College of Pharmacy, Duksung Women's University)
Lee, Yong-Soo (Dept. of Pabathophysiology & Pharmacology, College of Pharmacy, Duksung Women's University)
Publication Information
YAKHAK HOEJI / v.51, no.2, 2007 , pp. 96-102 More about this Journal
Abstract
Measurement of globotriaosylceramide (Gb3, ceramide trihexoside) in urine has clinical importance for monitoring after enzyme replacement therapy in Fabry disease patients. The disease is an X-linked lipid storage disorder that results from a deficiency of the enzyme ${\alpha}$-galactosidase A (${\alpha}$-Gal A). The lack of ${\alpha}$-Gal A causes an intracellular accumulation of glycosphingolipids, mainly Gb3. A simple, rapid, and highly sensitive analytical method for Gb3 in urine was developed without labor-extensive pre-treatment by electrospray ionization MS/MS (ESI-MS/MS). Only simple 5-fold dilution of urine is necessary for the extraction and isolation of Gb3 in urine. Gb3 in diluted urine was dissolved in dioxane containing C17:0 Gb3 as an internal standard. After centrifugation it was directly injected and analyzed through guard column by in combination with multiple reaction monitoring mode of ESI-MS/MS. Eight isoforms of Gb3 were completely resolved from urine matrix. C24:0 Gb3 occupied 50% of total Gb3 as a major component in urine. Linear relationship for Gb3 isoforms was found in the range of 0.005${\sim}$5.0 ${\mu}$g/ml. The limit of detection (S/N=5) was 0.005 ${\mu}$g/ml and limit of quantification was 0.05 ${\mu}$g/ml for C24:0 Gb3 with acceptable precision and accuracy. Correlation coefficient of calibration curves for 8 Gb3 isoforms ranged from 0.9598 to 0.9975. This method could be useful for rapid and sensitive 1st line Fabry disease screening, monitoring and/or diagnostic tool for Fabry disease.
Keywords
quantification; globotriaosylceramide (Gb3); MS/MS; fabry disease; screening;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Schiffmann, R., Murray, G. J., Trec, D., Daniel, P., Sellos-Moura, M., Myers, M., Quirk, J. M., Zirzow, G. C., Borowski, M., Loveday, K., Anderson, T., Gillespie, F., Oliver, K. L., Jeffries, N. O., Doo, E., Liang, T. J., Kreps, Gunter, C. K., Frei, K., Crutchfield, K., Selden, R. F. and O'Brady, R. O. : Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc. Natl. Acad. Sci. 97, 365 (2000)
2 Gross, S. K. and McCluer, R. H. : High-performance liquid chromatographic analysis of neutral glycosphingolipids as their per-O-benzoyl derivatives. Anal. Biochem. 102, 429 (1980)
3 Lee, W. M. F., Westrick, M. A. and Macher, B. A. : Highperformance liquid chromatography of long-chain neutral glycosphingolipids and gangliosides. Biochim. Biophys. Acta. 712, 498 (1982)
4 Strasberg, P. M., Warren, I., Skomorowski, M. A. and Lowden, J. A. : HPLC analysis of neutral glycolipids: an aid in the diagnosis of lysosomal storage disease. Clin. Chim. Acta. 132, 29 (1983)
5 Nelson, B. C., Roddy, T., Araghi, S., Wilkens, D., Thomas, J. J., Zhang, K., Sung, C. C. and Richards, S. M. : Globotriaosylceramide isoform profiles in human plasma by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 805(1), 127 (2004)   DOI   ScienceOn
6 Eng, C. M., Guffon, N., Wilcox, W. R., Germain, D. P., Lee, P., Waldek, S., Caplan, L., Linthorst, G. E. and Desnick, R. J. : Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry's disease. N. Engl. J. Med. 345(1), 9 (2001)
7 Ullman, M. D. and McCluer, R. : Quantitative microanalysis of perbenzoylated neutral glycosphingolipids by highperformance liquid chromatography with detection at 230 nm. J. Lipid Res. 19, 910 (1978)   PUBMED
8 Nelson, B. C., Roddy, T., Araghi, S., Wilkens, D., Thomas, J. J., Zhang, K., Sung, C. C. and Richards, S. M. : Globotriaosylceramide isoform profiles in human plasma by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 805(1), 127 (2004)   DOI   ScienceOn
9 Boscaro, F., Pieraccini, G., la Marca, G., Bartolucci, G., Luceri, C., Luceri, F. and Moneti, G. : Rapid quantitation of globotriaosylceramide in human plasma and urine: a potential application for monitoring enzyme replacement therapy in Anderson-Fabry disease. Rapid. Commun. Mass. Spectrom. 16(16), 1507 (2002)
10 Berna, L., Asfaw, B., Conzelmann, E., Cerny, B. and Ledvinova, J. : Determination of urinary sulfatides and other lipids by combination of reversed-phase and thin-layer chromatographies. Anal Biochem. 269(2), 304 (1999)
11 Schiffmann, R., Murray, G. J., Treco, D., Daniel, P., Sellos-Moura, M., Myers, M., Quirk, J. M., Zirzow, G. C., Borowski, M., Loveday, K., Anderson, T., Gillespie, F., Oliver, K. L., Jeffries, N. O., Doo, E., Liang, T. J., Kreps, C., Gunter, K., Frei, K., Crutchfield, K., Selden, R. F. and O'Brady, R. O. : Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc. Natl. Acad. Sci. 97, 365 (2000)
12 Thurberg, B. L., Rennke, H., Colvin, R. B., Dikman, S., Gordon, R. E., Collins, A. B., Desnick, R. J. and O'Callaghan, M. : Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int. 62, 1933 (2002)   DOI   ScienceOn
13 Zeidner, K. M., Desnick, R. J. and Ioannou, Y. A. : Quantitative determination of globotriaosylceramide by immunodetection of glycolipid-bound recombinant verotoxin B subunit. Anal. Biochem. 267, 104 (1999)
14 Fauler, G., Rechberger, G. N., Devrnja, D., Erwa, W., Plecko, B., Kotanko, P., Breunig, F. and Paschke, E. : Rapid determination of urinary globotriaosylceramide isoform profiles by electrospray ionization mass spectrometry usingstearoyl-d35-globotriaosylceramide as internal standard. Rapid. Commun. Mass. Spectrom. 19(11), 1499 (2005)   DOI   ScienceOn
15 Desnick, R. J., Brady, R., Barranger, J., Collins, A. J., Germain, D. P., Goldman, M., Grabowski, G., Packman, S. and Wilcox, W. R. : Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann. Int. Med. 138, 338 (2003)   DOI   ScienceOn
16 Frustaci, A., Chimenti, C., Ricci, R., Natale, L., Russo, M. A., Pieroni, M., Eng, C. M. and Desnick, R. J. : Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N. Engl. J. Med. 345(1), 25 (2001)
17 Barbey, F., Hayoz, D., Widmer, U. and Burnier, M. : Efficacy of enzyme replacement therapy in Fabry disease. Curr. Med. Chem. Cardiovasc. Hematol. Agents. 2(4), 277 (2004)   DOI   ScienceOn
18 Yoo, H. H., Son, J. and Kim, D. H. : Liquid chromatographytandem mass spectrometric determination of ceramides and related lipid species in cellular extracts. J Chromatogr. B 843(2), 327 (2006)   DOI   ScienceOn
19 Desnick, R. J., Brady, R., Barranger, J., Collins, A. J., Germain, D. P., Goldman, M. G., Packman, S., Wilcox, W. R. and Grabowski, J. : Fabry disease, an under-recognized multisystemic disorder : expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann. Intern. Med. 138(4), 338 (2003)   DOI   PUBMED   ScienceOn